article · Genetics & Applications
The aim of the study was to evaluate the prevalence of psychoactive substance abuse and association of single nucleotide polymorphisms in Cannabinoid-Receptor 1 (CNR1) gene with chronic polysubstance use among the Nigerian male commercial vehicle drivers selected from the three major ethnic groups in Nigeria. A-10-Panel Generic Multi Drug Urine Dip Card Test Kit was used in the study and four SNPs (rs2023239, rs806378, rs806379 and rs806381)in CNR1 were genotyped in 60 subjects (20 drivers from each ethnic group) by using Sequenom MassARRAY Genotyping System. The four target SNPs revealed the following genotypes namely rs2023239: CC (20%), CT (40%), TT (40%); rs806378: CC (100%); rs806379: AA (20%), AT (50%), TT (30%); rs806381: AA (50%), GA (50%) in cases among the Hausa drivers. However, among the Igbo drivers, the four target SNPs showed the following genotypes namely rs2023239: CC (20%), CT (40%), TT (40%); rs806378: CC (80%) CT (20%); rs806379: AA (10%), AT (50%), TT (40%) and rs806381: AA (30%), GA (70%) in cases. Additionally, the target SNPs also revealed the following genotypes namely rs2023239: CC (30%), CT (30%), TT (40%); rs806378: CC (90%), CT (10%); rs806379: AA (10%), AT (60%), TT (30%) and rs806381: AA (70%), GA (20%), GG (10%) in cases among the Yoruba drivers. The SNPs rs2023239, rs806378 and rs806381 were significantly linked with polysubstance and chronic cannabis use in the sample population (Hausa, Igbo and Yoruba) (p˂0.05). The SNP rs806379 associated significantly with polysubstance and chronic cannabis use in the Igbo drivers only (p˂0.05). Conclusively, this study provides probably the first data on the association of CNR1genetic polymorphism with chronic polysubstance use among Nigerian male commercial motor vehicle drivers.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.31383/ga.vol8iss1ga01
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.